QualiCOP: an open-label, prospective, observational study of glatiramer acetate in patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Ziemssen, T. [1 ]
Calabrese, P. [2 ]
Penner, I. -K. [2 ]
Carroll, C. A. [3 ]
Apfel, R. [4 ]
机构：
[1] Univ Clin Carl Gustav Carus, Dresden, Germany
[2] Univ Basel, Basel, Switzerland
[3] Teva Pharmaceut Ind, Global Hlth Econ & Outcomes Res, Overland Pk, KS USA
[4] Teva Pharmaceut Ind, Berlin, Germany
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2014年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP4140
引用
收藏
页码：340 / 340
页数：1
相关论文
共 50 条
  • [41] Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
    Laura Ordoñez-Boschetti
    Roberto Rey
    Ana Cruz
    Arijit Sinha
    Tracy Reynolds
    Nadina Frider
    Regina Alvarenga
    [J]. Advances in Therapy, 2015, 32 : 626 - 635
  • [42] Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study
    Totaro, Rocco
    Di Carmine, Caterina
    Costantino, Gianfranco
    Fantozzi, Roberta
    Bellantonio, Paolo
    Fuiani, Aurora
    Mundi, Ciro
    Ruggieri, Stefano
    Marini, Carmine
    Carolei, Antonio
    [J]. MULTIPLE SCLEROSIS INTERNATIONAL, 2015, 2015
  • [43] Glatiramer acetate (Copaxone) treatment in relapsing-remitting multiple sclerosis: Quantitative MR assessment
    Ge, Y
    Grossman, RI
    Udupa, JK
    Fulton, JC
    Babb, JS
    Constantinescu, CS
    [J]. RADIOLOGY, 1999, 213P : 441 - 441
  • [44] Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
    Khan, Omar
    Rieckmann, Peter
    Boyko, Alexey
    Selmaj, Krzysztof
    Ashtamker, Natalia
    Davis, Mat D.
    Kolodny, Scott
    Zivadinov, Robert
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (06) : 818 - 829
  • [45] Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis
    Boster, Aaron L.
    Ford, Corey C.
    Neudorfer, Orit
    Gilgun-Sherki, Yossi
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (06) : 575 - 586
  • [46] Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis
    Kalincik, Tomas
    Jokubaitis, Vilija
    Izquierdo, Guillermo
    Duquette, Pierre
    Girard, Marc
    Grammond, Pierre
    Lugaresi, Alessandra
    Oreja-Guevara, Celia
    Bergamaschi, Roberto
    Hupperts, Raymond
    Grand'Maison, Francois
    Pucci, Eugenio
    Van Pesch, Vincent
    Boz, Cavit
    Iuliano, Gerardo
    Fernandez-Bolanos, Ricardo
    Flechter, Shlomo
    Spitaleri, Daniele
    Cristiano, Edgardo
    Verheul, Freek
    Lechner-Scott, Jeannette
    Amato, Maria Pia
    Antonio Cabrera-Gomez, Jose
    Saladino, Maria Laura
    Slee, Mark
    Moore, Fraser
    Gray, Orla
    Paine, Mark
    Barnett, Michael
    Havrdova, Eva
    Horakova, Dana
    Spelman, Timothy
    Trojano, Maria
    Butzkueven, Helmut
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (09) : 1159 - 1171
  • [47] Glatiramer acetate induced gene expression regulatory networks in relapsing-remitting multiple sclerosis
    Achiron, A
    Snir, Y
    Feldman, A
    Gurevich, M
    [J]. NEUROLOGY, 2006, 66 (05) : A370 - A370
  • [48] Gene Expression Biomarkers for Glatiramer Acetate Treatment Response in Relapsing-Remitting Multiple Sclerosis
    Anis, Saar
    Sonis, Polina
    Hanael, Erez
    Gurevich, Michael
    Achiron, Anat
    [J]. NEUROLOGY, 2013, 80
  • [49] Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose - is more better?
    Calabresi, Peter A.
    [J]. NATURE CLINICAL PRACTICE NEUROLOGY, 2007, 3 (10): : 540 - 541
  • [50] Efficacy and safety of a 3 times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
    Khan, O.
    Rieckmann, P.
    Boyko, A. N.
    Selmaj, K. W.
    Ashtamker, N.
    Davis, M. D.
    Kolodny, S.
    Zivadinov, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 711 - 711
12345